Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality

5 Nov 2024

Abstract excerpt

BACKGROUND: PARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However, mutations in BRCA1/2 are notably rare in pancreatic cancer. OBJECTIVE: There is a significant unmet clinical need to broaden the utility of PARPi. DESIGN: RNA sequencing was performed to screen potential targets for PARPi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39500552
DOI: 10.1136/gutjnl-2024-332782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethalityPMID 39500552Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

Evolving DNA repair synthetic lethality targets in cancerSemantic proximity Read ↗

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read ↗

DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparibSemantic proximity Read ↗

Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical ApplicationSemantic proximity Read ↗

Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application.Semantic proximity Read ↗

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancerSemantic proximity Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with OlaparibSemantic proximity Read ↗

Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation ResponseSemantic proximity Read ↗

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.